pediatrics-congress-2019-posters-abstracts

Page 46

Volume 03

Stem Cells 2019 & Pediatrics Congress 2019

November 06-07, 2019

Journal of Child and Adolescent Psychiatry

November 06-07, 2019 | Tokyo, Japan

STEM CELLS AND REGENERATIVE MEDICINE

PEDIATRICS AND CHILD CARE

International Conference on

World Congress on

J Child Adolesc Psych, Volume 03

The remarkable effects of “ASEA redox supplement” in a Child with Duchenne

Muscular Dystrophy: A case report from Romania, Southeastern Europe

Andrei-Lucian Drăgoi

University of Medicine and Pharmacy, Romania

Statement of the Problem

: Children diagnosed with Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD)

(with an estimated global incidence of more than 1 million new DMD/BMD children cases each 4 years worldwide) before the age

of 4 (years old) have only few practical early treatment options other than physical therapy and early corticosteroids (ECs) on long-

term before this age, which ECs have many adverse effects, especially in children under development with chronic treatment with

ECs (chronic immunosuppression, growth delay, osteoporosis, obesity, water and salt retention, potassium loss, muscular loss and

weakness, gastrointestinal and hepatic problems and diseases etc).

Methodology & Theoretical Orientation

Findings

: This research aims at discovering dietary supplements which may show

comparable or even stronger beneficial effects (as early as possible after the moment of DMD/BMD diagnosis) with less or none

adverse effects when compared to early or late corticosteroids in children with DMD and BMD.

Conclusion & Significance

: This paper presents a case report on the effects of an ionized “saline water” called “ASEA redox

supplement®” (ARS) oral solution in a ~2-year-old boy with DMD from Bucharest, Romania.

In vitro

studies showed that ARS is a

very potent selective NRF2 activator: the studies conducted

in vivo

also support this main pharmacological mechanism of ARS, with

no toxicity up to high doses, in contrast with the much more toxic corticosteroids. From the first months of ARS treatment all the

rhabdomyolysis markers (with very high initial serum levels) dropped significantly, with no found toxicity. In conclusion and given

its very strong antioxidant effects (

in vivo

and

in vitro

) on the skeletal muscles and myocardium, ARS should be studied on larger

groups of children with DMD and BMD under the age of 4 years old (as a much better alternative to ECs and the potential to fully

replace ECs), but ARS may be also studied on many other acute and chronic muscular and cardiovascular diseases, with potential of

ameliorating the condition of millions and even billions of children and adult patients worldwide.